Promises
4 promises
Promise Tracker
0 delivered, 0 close, 4 missed.
View Promises →
Ajanta Pharma Limited — Q3 FY26
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 1,375 crore (+20% YoY) and EBITDA of INR 382 crore (+19% YoY).
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 1,375 crore (+20% YoY) and EBITDA of INR 382 crore (+19% YoY). PAT grew 18% YoY to INR 274 crore. Growth was led by the US generics business (+52% YoY to INR 399 crore) driven by new product launches and market share gains, and India branded business (+19% YoY to INR 409 crore) outperforming IPM. Africa branded grew 33% YoY, while Asia branded declined 9% YoY due to softer traction in select markets. Management maintained EBITDA margin guidance of 27%±1% for FY26 and expects gross margin around 78%±1%. Key strategic initiatives include GLP-1 partnership with Biocon for 26 countries (launch from FY27-28) and active M&A pipeline with INR 1,000+ crore earmarked. Risk: Asia branded recovery may take longer than expected if market softness persists.
अजंता फार्मा की तीसरी तिमाही (अक्टूबर-दिसंबर 2025) में कमाई 1,375 करोड़ रुपये रही, जो पिछले साल से 20% ज्यादा है। कंपनी का मुनाफा (EBITDA) 382 करोड़ रुपये (+19%) और शुद्ध मुनाफा (PAT) 274 करोड़ रुपये (+18%) हुआ। अमेरिका में जेनेरिक दवाओं की बिक्री 52% बढ़कर 399 करोड़ रुपये हो गई, क्योंकि नई दवाएं लॉन्च हुईं और बाजार हिस्सेदारी बढ़ी। भारत में ब्रांडेड दवाओं की बिक्री 19% बढ़कर 409 करोड़ रुपये रही। अफ्रीका में 33% बढ़ोतरी हुई, लेकिन एशिया में 9% गिरावट आई। कंपनी ने पूरे साल 27% मुनाफा मार्जिन और 78% सकल मार्जिन का अनुमान रखा है। आगे की योजना: बायोकॉन के साथ मिलकर GLP-1 दवा (मधुमेह/मोटापे की) 26 देशों में लॉन्च करना (2027-28 से) और 1,000 करोड़ रुपये से अधिक का निवेश। जोखिम: एशिया में बाजार सुस्त रहा तो रिकवरी में देरी हो सकती है।
Promises0 met · 4 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Asia branded business recovery uncertainty
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Generics Revenue
INR 399 crore
+52% YoY
Driven by 8 new product launches over 12 months and seasonal flu product.
India Branded Revenue
INR 409 crore
+19% YoY
Outperformed IPM growth of 9%; volume growth 1.5x IPM.
Africa Branded Revenue
INR 230 crore
+33% YoY
Stronger than anticipated; surpassed internal plans for quarter and 9M.
Asia Branded Revenue
INR 288 crore
-9% YoY
Below internal plans due to softer traction in few markets; recovery expected from Q4.
What Changed vs Last Quarter
NEW
Gross margin around 78%±1% for FY26
Gross margin expected to remain around 78%±1% for the full year.
NEW
US generics double-digit growth in FY27
Management expects US generics to post double-digit growth in FY27, though growth rate may moderate from FY26 levels.
UPDATED
EBITDA margin guidance of 27%±1% for FY26
Management reiterated EBITDA margin guidance of 27%±1% for the full year, excluding mark-to-market forex impact.
UPDATED
Capex guidance of ~INR 300 crore for FY26
Capital expenditure for 9M stood at INR 235 crore; full year guidance of around INR 300 crore.
DROPPED
US generics to sustain current run rate in H2
US generics revenue run rate of ~INR 343 crore per quarter is expected to be sustained for the next two quarters.
DROPPED
Africa business to achieve double-digit growth in FY26
Africa business guidance upgraded from mid-single-digit to double-digit growth for the full year.
NEW RISK
Asia branded business recovery uncertainty
Asia branded declined 9% YoY due to softer traction in certain markets; management expects recovery from Q4 but no specific timeline.
NEW RISK
Competition in GLP-1 market in India
Analyst raised concern about aggressive competition in India for GLP-1; management acknowledged 15-20+ competitors expected.
NEW RISK
Execution risk in new geographies and M&A
Management mentioned potential entry into Latin America and active M&A pipeline; execution and integration risks are high.
RISK GONE
IQVIA data anomaly in cardiology segment
IQVIA reports Ajanta's cardiology growth at 6% vs IPM's 12%, but management claims internal sales match IPM; discrepancy unresolved.
RISK GONE
Africa business base effect and moderated growth
Africa pharma market expected moderated growth; high base of previous year could weigh on growth despite upgraded guidance.
RISK GONE
Inventory days may inch up from current low levels
Management noted current 56-day inventory is not sustainable and expects it to rise to ~65 days, potentially impacting working capital.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25, Q4 FY25
The Africa institutional segment declined 53% in Q4 and remains unpredictable due to donor funding uncertainties, including potential USAID cuts.
Mentioned in Q1 FY25, Q2 FY25, Q4 FY25
Management expects branded generic business to grow in low teens and US generics in high teens, driven by new product launches and market share gains.
Mentioned in Q1 FY26, Q2 FY26
Africa business guidance upgraded from mid-single-digit to double-digit growth for the full year.
Mentioned in Q1 FY26, Q2 FY26
Mark-to-market forex losses of INR 41 crore in Q2 distorted EBITDA margin; continued volatility could mask underlying performance.
Mentioned in Q1 FY25, Q4 FY25
Management expects to file 10-12 ANDAs in FY26, with a robust pipeline and several products in advanced stages.
Fast read
Guidance and risk preview
Management reiterated EBITDA margin guidance of 27%±1% for the full year, excluding mark-to-market forex impact.
Asia branded declined 9% YoY due to softer traction in certain markets; management expects recovery from Q4 but no specific timeline.
View Risks →